Jones Lang LaSalle Inc vs Liquidia Corporation Common Stock — how do they compare? Jones Lang LaSalle Inc trades at $294.36 (market cap $13.73B), while Liquidia Corporation Common Stock trades at $33.78 (market cap $2.40B). The key difference: Jones Lang LaSalle Inc is far larger — about 5.7× Liquidia Corporation Common Stock's market cap, and Jones Lang LaSalle Inc is more actively traded (368,437 versus 2,857,547). Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and Liquidia Corporation Common Stock for 0 Days on average.
| JLL | LQDA | |
|---|---|---|
Market Cap | $13.73B | $2.40B |
Volume | 368,437 | 2,857,547 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $91.03 |
52-Week Low | $280.16 | $22.02 |
Typical Hold Time | 71 Days | 0 Days |
Enterprise Value | $16.49B | $2.30B |
Signals from Pluang's Aura AI — not financial advice
JLL trades at $295.25, down 0.96% on the day, reflecting near-term pressure amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, revenue growth from $20.9B in 2022 to $26.1B in 2025, and improving net margins. Recent acquisitions and strategic appointments highlight operational momentum, while analyst consensus remains bullish with a $450.50 price target.
The outlook is positive given valuation discounts (P/E 14.31, P/S 0.52) and robust cash flow growth, though risks include real estate market cyclicality and technical resistance near $297. Upside hinges on continued execution and sector tailwinds, supporting a constructive view for long-term investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →